菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

 

Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized both as standalone molecules and as building blocks of bispecific antibodies. However, their production and engineering face numerous challenges, including issues related to yield, purity, throughput, and stability. In this webinar, we will unveil innovative strategies to overcome these challenges, tailored to the distinctive characteristics of Fab, ScFv, and VHH. We’ll provide key insights into molecular design, high-titer CHO transient and stable pool production, and effective purification methods to accelerate your development of antibody fragments.

 

In this webinar, you will learn:

 

Novel strategies to tackle common production challenges like low yields, throughput issues, and impurities in antibody fragment production.

Advanced molecule engineering and linker design to mitigate aggregation and increase yield.

Tailored approaches for optimizing the production of Fab, ScFv, and VHH, with a focus on specific strategies for each fragment type.

 

 

Webinar Details

 

Date: Wednesday, April 24, 2024

Time: 8:00 AM PT | 11:00 AM ET

 

 

Speaker:

 

 

 

Jiansheng Wu, Ph.D.

Senior VP, Head of CRO Services

 

Dr. Wu is the Head of CRO Services and Senior VP at WuXi Biologics. With vast experience and expertise in protein sciences, he has been instrumental in establishing global protein production facilities and developing cutting-edge technologies. Having participated in over 50 drug development projects, Dr. Wu is a leading authority in automated expression, purification, and characterization of diverse proteins. Previously at Genentech for 15 years, he made significant contributions to innovative protein expression and purification technologies.

Enter your information to watch the recording

 

Have specific questions about Fab, scFv & VHH production?

Reach out to our experts!